| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 135, 290-298, Copyright © 1994 by Endocrine Society
ARTICLES |
C Missale, F Boroni, S Sigala, A Zanellato, R Dal Toso, A Balsari and P Spano
Department of Biomedical Sciences and Biotechnology, University of Brescia School of Medicine, Italy.
GH-3 is an established cell line which, for the production of both PRL and GH, may be related to the bipotential somatomammotroph from which both somatotroph and mammotroph cells derive. In the present study we first report that GH-3 cells express both the gp140trk and the gp75 components of the nerve growth factor (NGF) receptor and that NGF dictates a nonneuronal type of differentiation of this cell line of ectodermal origin. After exposure to NGF, GH-3 cells markedly decreased their proliferation rate. This effect, which was maximal (50% inhibition) 3 days after beginning the treatment and was maintained during the following days of exposure, was paralleled by a change in the hormone production. The secretion of PRL was increased 6-fold, but that of GH was remarkably inhibited. Moreover, GH-3 cells expressed the mammotroph-specific D-2 receptor protein in response to NGF, as shown by binding with the D-2 receptor ligand N-(p-aminophenetyl)spiperone coupled to fluorescein. The present data thus show that NGF induces the differentiation of GH-3 cells into one of their physiological counterparts, the mammotroph cell, and together with the finding that NGF receptors are expressed in the anterior pituitary suggest a physiological role for the neurotrophic factor in pituitary ontogenesis.
This article has been cited by other articles:
 |
|
 |
|
  A. M. Lopez-Dominguez, J. L. Espinosa, A. Navarrete, G. Avila, and G. Cota Nerve growth factor affects Ca2+ currents via the p75 receptor to enhance prolactin mRNA levels in GH3 rat pituitary cells J. Physiol., July 15, 2006; 574(2): 349 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schwartz Intercellular Communication in the Anterior Pituitary Endocr. Rev., October 1, 2000; 21(5): 488 - 513. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: Structure, Function, and Regulation of Secretion Physiol Rev, October 1, 2000; 80(4): 1523 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Asa, M. A. Kelly, D. K. Grandy, and M. J. Low Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice Endocrinology, November 1, 1999; 140(11): 5348 - 5355. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Stahl, S. K. Kendall, M. L. Brinkmeier, T. L. Greco, D. E. Watkins-Chow, A. Campos-Barros, R. V. Lloyd, and S. A. Camper Thyroid Hormone Is Essential for Pituitary Somatotropes and Lactotropes Endocrinology, April 1, 1999; 140(4): 1884 - 1892. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Asa and S. Ezzat The Cytogenesis and Pathogenesis of Pituitary Adenomas Endocr. Rev., December 1, 1998; 19(6): 798 - 827. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. Missale, A. Codignola, S. Sigala, A. Finardi, M. Paez-Pereda, E. Sher, and P. Spano Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines PNAS, April 28, 1998; 95(9): 5366 - 5371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON Dopamine Receptors: From Structure to Function Physiol Rev, January 1, 1998; 78(1): 189 - 225. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
